Add office photos
Employer?
Claim Account for FREE
Lupin
4.1
based on 6.3k Reviews
Video summary
Company Overview
Associated Companies
Company Locations
Working at Lupin
Company Summary
A leading global pharmaceutical company in India
Overall Rating
4.1/5
based on 6.3k reviews
5% above
industry average
Highly rated for
Company culture, Skill development, Work-life balance
Work Policy
Work from office
86% employees reported
Monday to Saturday
58% employees reported
Flexible timing
53% employees reported
No travel
47% employees reported
View detailed work policy
Top Employees Benefits
Job/Soft skill training
532 employees reported
Health insurance
476 employees reported
Office cab/shuttle
327 employees reported
Cafeteria
211 employees reported
View all benefits
About Lupin
Founded in1968 (57 yrs old)
India Employee Count10k-50k
Global Employee Count10k-50k
India HeadquartersMumbai, Maharashtra, India
Office Locations
Websitelupin.com
Primary Industry
Other Industries
Are you managing Lupin's employer brand? To edit company information,
claim this page for free
View in video summary
Lupin is a global pharmaceutical company offering a wide range of products such as Branded & Generic Formulations, Biotechnology Products, Active Pharmaceutical Ingredients (APIs) and Specialty. Lupin is a significant player in the therapy areas of Gynaecology, Cardiovascular, Diabetology, Asthma, Paediatric, Central Nervous System (CNS), Gastro Intestinal (GI), Anti-Infective (AI) and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Lupin also holds a global leadership position in the Anti-TB and Cephalosporins segments. With a presence in over 100 countries, Lupin offers high-quality yet affordable medicines for some of the most chronic diseases addressing unmet needs in many parts of the world.
Managing your company's employer brand?
Claim this Company Page for FREE
Lupin Ratings
based on 6.3k reviews
Overall Rating
4.1/5
How AmbitionBox ratings work?
5
3.2k
4
1.8k
3
709
2
224
1
383
Category Ratings
4.0
Company culture
4.0
Skill development
3.9
Work-life balance
3.8
Salary
3.8
Work satisfaction
3.7
Job security
3.5
Promotions
Lupin is rated 4.1 out of 5 stars on AmbitionBox, based on 6.3k company reviews. This rating reflects a generally positive employee experience, indicating satisfaction with the company’s work culture, benefits, and career growth opportunities. AmbitionBox gathers authentic employee reviews and ratings, making it a trusted platform for job seekers and employees in India.
Read more
Gender Based Ratings at Lupin
based on 6.1k reviews
4.0
Rated by 382 Women
Rated 3.9 for Work-life balance and 3.9 for Company culture
4.1
Rated by 5.7k Men
Rated 4.1 for Skill development and 4.0 for Company culture
Work Policy at Lupin
based on 670 reviews in last 6 months
Work from office
86%
Hybrid
9%
Permanent work from home
5%
Lupin Reviews
Top mentions in Lupin Reviews
+ 5 more
Compare Lupin with Similar Companies
Change Company | Change Company | Change Company | ||
|---|---|---|---|---|
Overall Rating | 4.1/5 based on 6.3k reviews | 4.1/5 based on 6.2k reviews | 4.0/5 based on 7.1k reviews | 4.1/5 based on 7.2k reviews |
Highly Rated for | Skill development Company culture Work-life balance | Salary Skill development Job security | Skill development Company culture Work-life balance | Skill development Salary Work-life balance |
Critically Rated for | No critically rated category | No critically rated category | Promotions | No critically rated category |
Primary Work Policy | Work from office 86% employees reported | Work from office 82% employees reported | Work from office 75% employees reported | Work from office 72% employees reported |
Rating by Women Employees | 4.0 Good rated by 382 women | 4.0 Good rated by 399 women | 4.0 Good rated by 801 women | 4.0 Good rated by 726 women |
Rating by Men Employees | 4.1 Good rated by 5.7k men | 4.1 Good rated by 5.2k men | 4.1 Good rated by 5.9k men | 4.1 Good rated by 6.1k men |
Job security | 3.7 Good | 3.9 Good | 3.5 Good | 3.7 Good |
View more
Lupin Salaries
Lupin salaries have received with an average score of 3.8 out of 5 by 6.3k employees.
Officer
(1.8k salaries)
Unlock
₹1.9 L/yr - ₹8.9 L/yr
Research Associate
(838 salaries)
Unlock
₹2 L/yr - ₹8.6 L/yr
Production Officer
(555 salaries)
Unlock
₹2 L/yr - ₹6.4 L/yr
Senior Officer
(456 salaries)
Unlock
₹2.6 L/yr - ₹7.5 L/yr
Junior Officer
(396 salaries)
Unlock
₹2.5 L/yr - ₹8 L/yr
Medical Representative
(360 salaries)
Unlock
₹2.3 L/yr - ₹6.5 L/yr
Marketing Executive
(341 salaries)
Unlock
₹2.2 L/yr - ₹7.1 L/yr
Area Sales Manager
(340 salaries)
Unlock
₹4.2 L/yr - ₹10.1 L/yr
Executive Production
(286 salaries)
Unlock
₹3.6 L/yr - ₹12 L/yr
Quality Control Officer
(259 salaries)
Unlock
₹2.7 L/yr - ₹5.7 L/yr
Lupin Interview Questions
Interview questions by designation
Top Lupin interview questions and answers
Get interview-ready with top interview questions
Lupin Jobs
Current Openings
Lupin News
View all
Lupin-led price cut slashes cost of key TB drug pretomanid by 25%
- The Stop TB Partnership’s Global Drug Facility (GDF) announced a 25 percent price reduction for pretomanid produced by Lupin.
- The reduced price of $169 per treatment course will save GDF clients upwards of $3 million per year.
- The price reduction is part of a multi-manufacturer approach to improve access and affordability of TB drugs.
- The cost of a BPaL/M treatment course has dropped to $310, enabling the treatment of an additional 120,000 people with DR-TB.
HinduBusinessLine | 25 Apr, 2025
Lupin gets USFDA nod for generic kidney disease treatment drug
- Lupin has received approval from the USFDA for the generic version of Tolvaptan, a drug used for treating kidney disease.
- The approved drug is bioequivalent to Jynarque, a tablet manufactured by Otsuka Pharmaceutical.
- Lupin is the exclusive first-to-file for this product and is eligible for 180 days of generic drug exclusivity.
- Tolvaptan is indicated to slow kidney function decline in adults with autosomal dominant polycystic kidney disease (ADPKD).
HinduBusinessLine | 24 Apr, 2025
Heard On The Street: Dealers Spot Action In IIFL Finance, Zydus Life, Lupin And Select IT Stocks
- IIFL Finance witnessed strong domestic institutional buying.
- Zydus Life and Lupin received positional buy calls in multiple dealing rooms.
- IT stocks like Tech Mahindra and Coforge attracted investor focus.
- Delivery-based buying continued in select IT names.
Bloomberg Quint | 22 Apr, 2025
Six Stocks In News At Noon: Wipro, Waaree Renewable Technologies, Lupin, Sonata Software, Among Others
- Wipro's share price fell over 6% after issuing a weak revenue outlook for the June quarter.
- Lupin Ltd. gained 1.43% despite an ongoing patent dispute ruling in favor of Astellas Pharma.
- Cello World Ltd. jumped 7.37% after being upgraded to 'buy' by Kotak Institutional Securities.
- Sonata Software Ltd. fell over 14% after warning of a revenue decline from its largest client in the March quarter.
Bloomberg Quint | 17 Apr, 2025
Zydus, Lupin Shares: Systematix Retains Hold, Cuts Target Price Over US Court Ruling In Myrbetriq Patent Case
- The US Court ruling in the Myrbetriq patent case has led Systematix to retain a hold rating on shares of Zydus and Lupin.
- Systematix has also cut the target price due to the court ruling which blocks the sale of generic versions of Myrbetriq in the US until the patent expires in March 2030.
- Lupin and Zydus Life had filed ANDAs with the USFDA to market generic versions of Myrbetriq, but their plans have been halted by the court ruling.
- The patent challenge made by Lupin and Zydus Life was rejected by the US District Court for the District of Delaware.
Bloomberg Quint | 17 Apr, 2025
Lupin Share Price Rises As Nomura Stays Positive Amid Patent Litigation
- Lupin's share price rose as Nomura maintained a positive rating amid patent litigation.
- The United States District Court ruled in favor of Astellas Pharma in a patent infringement case against Lupin's generic product.
- Nomura believes there is a strong possibility of generics prevailing in the litigation.
- Lupin's stock rose by 1.43% to Rs 1,961.90 apiece.
Bloomberg Quint | 17 Apr, 2025
.png?rect=0%2C18%2C483%2C254&w=1200&auto=format%2Ccompress&ogImage=true)
Stock Market Live: GIFT Nifty Implies Higher Open; Angle One, Wipro, Lupin, Paytm Share Prices In Focus
- Gold prices hit a record high again due to uncertainty over international trade and the US Federal Reserve's indication of no hurry to reduce interest rates.
- Oil prices rose for a second day as the US vowed to pressure Iran's oil exports and oil inventory declined at Cushing Oklahoma.
- Most markets in the Asia-Pacific region traded higher on progress in trade talks between the US and Japan.
- US share indices fell as concerns over the impact of US tariffs and Federal Reserve Chair Jerome Powell's comments on interest rates rose.
Bloomberg Quint | 17 Apr, 2025
Stock Recommendations Today: Wipro, Adani Ports, Angel One, Bharti Airtel, IndiGo On Brokerages' Radar
- Wipro Ltd. faced negative brokerage commentary after issuing weaker-than-expected revenue guidance and highlighting client uncertainty due to global tariff concerns.
- Brokerages like Citi, BofA Securities, and Investec trimmed price targets and earnings estimates for Wipro, anticipating another challenging year for the tech major.
- Morgan Stanley adjusted targets for consumer discretionary names, supporting disruptors like Trent Ltd. and raising price targets for Interglobe Aviation Ltd. in the travel sector.
- Analysts shared their recommendations on various stocks, with Citi retaining a 'sell' rating on Wipro and BofA Securities expecting a growth catch-up in the future.
- Morgan Stanley analyzed companies like Vedant Fashions, Aditya Birla Fashion, Trent, and Brainbees Solutions within the consumer discretionary segment, favoring businesses with strong competitive advantages.
- Adani Ports received positive feedback from Morgan Stanley for its resilient business model and strategy to reduce Ebitda sensitivity to cargo volumes.
- Angel One was recommended as a 'buy' by Investec, with noted earnings growth weaknesses in the upcoming fiscal year.
- HSBC raised the price target on InterGlobe Aviation and noted strong trading trends in the travel and hospitality sector.
- Bharti Airtel was highlighted by Bernstein as a top pick in the telecom sector, supported by strong defensive attributes and ongoing deleveraging.
- UBS shared insights on the Mirabegron litigation outcome, indicating potential challenges for Zydus and Lupin in the pharmaceutical space.
Bloomberg Quint | 17 Apr, 2025
Stock Market Today: All You Need To Know Going Into Trade On April 17
- Indian benchmark indices closed higher for the third consecutive session with NSE Nifty 50 up by 0.47% and BSE Sensex up by 0.4% on Wednesday.
- Foreign portfolio investors continued as net buyers of Indian equities, while domestic institutional investors were net sellers on Wednesday.
- Key earnings post-market hours included updates from companies like Wipro, Waaree Renewable Technologies, Angel One, and GTPL Hathway.
- Stocks to watch include Zydus Lifesciences, Lupin, One 97 Communications, Gensol Engineering, UltraTech Cement, DLF, and others.
- Notable market developments include ongoing investments, acquisitions, agreements, dividend announcements, and trading tweaks in various companies.
- Bulk/block deals involved companies like Gensol Engineering and Sami Hotels, with trading tweaks seen in securities like Garware Hi-Tech Films Ltd.
- In the F&O segment, Nifty April Futures rose, open interest fell, and specific securities were put under the F&O ban category.
- The Indian rupee strengthened against the US dollar, closing at 85.68 on Wednesday, supported by factors like easing inflation and lower oil prices.
- Overall, the stock market landscape showed positive movements in key indices and various corporate actions influencing investor sentiment.
- Market participants should closely monitor these developments and company-specific news for potential investment opportunities or risks.
Bloomberg Quint | 17 Apr, 2025
Stocks that will see action today: April 3, 2025
- HDFC Bank receives warning letter from SEBI for regulatory non-compliance.
- Punjab National Bank reports 13.6% credit growth and 14.3% rise in total deposits.
- Shree Cement commissions new grinding unit at Etah, with an annual capacity of 3 MTPA.
- Lupin acquires UK-based Renascience Pharma for 12.3 million pounds.
HinduBusinessLine | 3 Apr, 2025
Powered by
Lupin Subsidiaries
Rubamin
4.2
• 163 reviews
Lupin Digital Health
3.5
• 33 reviews
Polynova Industries
4.1
• 8 reviews
Novel Laboratories Inc
2.0
• 1 review
Report error
Compare Lupin with
Sun Pharmaceutical Industries
4.0
Aurobindo Pharma
4.0
Intas Pharmaceuticals
4.1
Hetero
3.9
Viatris
4.1
Alembic Pharmaceuticals
4.0
Abbott
4.1
Ipca Laboratories
3.9
Glenmark Pharmaceuticals
3.9
Alkem Laboratories
3.9
Torrent Pharmaceuticals
3.9
Mankind Pharma
3.9
MSN Laboratories
3.7
Ajanta Pharma
4.0
Akums Drugs & Pharmaceuticals Limited
4.4
GlaxoSmithKline Pharmaceuticals
4.1
Pfizer
3.9
DIVI'S Laboratories
3.7
Wockhardt
3.9
Teva Pharmaceuticals
4.0
Edit your company information by claiming this page
Contribute & help others!
You can choose to be anonymous
Write a review
Share interview
Contribute salary
Add office photos
Companies Similar to Lupin
Cipla
Manufacturing, Pharma
4.1
• 7.2k reviews
Dr. Reddy's
Clinical Research, Pharma
4.0
• 7.1k reviews
Zydus Lifesciences
Biotech & Life sciences, Pharma
4.1
• 6.2k reviews
Sun Pharmaceutical Industries
Healthcare / Pharma, Manufacturing, Analytics & KPO, Pharma
4.0
• 6.1k reviews
Aurobindo Pharma
Healthcare / Pharma, Biotechnology, Pharma
4.0
• 5k reviews
Intas Pharmaceuticals
Biotech & Life sciences, Pharma
4.1
• 3.6k reviews
Alembic Pharmaceuticals
Real Estate, Engineering & Construction, Biotechnology, Pharma
4.0
• 3.2k reviews
Abbott
Healthcare / Pharma, Media & Entertainment / Publishing, Pharma
4.1
• 3.2k reviews
Ipca Laboratories
Pharma
3.9
• 3.1k reviews
Glenmark Pharmaceuticals
Pharma
3.9
• 3.1k reviews
Lupin FAQs
When was Lupin founded?
Lupin was founded in 1968. The company has been operating for 57 years primarily in the Pharma sector.
Where is the Lupin headquarters located?
Lupin is headquartered in Mumbai, Maharashtra and has an office in Mumbai
How many employees does Lupin have in India?
Lupin currently has more than 21,000+ employees in India. Research & Development department appears to have the highest employee count in Lupin based on the number of reviews submitted on AmbitionBox.
Does Lupin have good work-life balance?
Lupin has a Work-Life Balance Rating of 3.9 out of 5 based on 6,300+ employee reviews on AmbitionBox. 79% employees rated Lupin 4 or above, while 21% employees rated it 3 or below on work-life balance. This indicates that the majority of employees feel a generally balanced work-life experience, with some opportunities for improvement based on the feedback. We encourage you to read Lupin work-life balance reviews for more details
Is Lupin good for career growth?
Career growth at Lupin is rated fairly well, with a promotions and appraisal rating of 3.5. 79% employees rated Lupin 4 or above, while 21% employees rated it 3 or below on promotions/appraisal. Though the sentiment is mixed for career growth, majority employees have rated it positively. We recommend reading Lupin promotions/appraisals reviews for more detailed insights.
What are the pros of working in Lupin?
Working at Lupin offers several advantages that make it an appealing place for employees. The company is highly rated for company culture, skill development and work life balance, based on 6,300+ employee reviews on AmbitionBox.
Recently Viewed
LIST OF COMPANIES
CQENT
Overview
REVIEWS
Indamer
No Reviews
SALARIES
Zelis
No Salaries
REVIEWS
Nimbeon
No Reviews
LIST OF COMPANIES
DELTA
Overview
COMPANY BENEFITS
DELTA
No Benefits
REVIEWS
AskCred
No Reviews
Stay ahead in your career. Get AmbitionBox app
Helping over 1 Crore job seekers every month in choosing their right fit company
75 Lakh+
Reviews
5 Lakh+
Interviews
4 Crore+
Salaries
1 Cr+
Users/Month
Contribute to help millions
Get AmbitionBox app
Made with ❤️ in India. Trademarks belong to their respective owners. All rights reserved © 2024 Info Edge (India) Ltd.
Follow us
